27 Drydock Avenue
8th Floor
Boston, MA 02210
United States
877 422 5362
https://www.ginkgobioworks.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 1.218
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Jason Kelly | Founder, CEO & Director | 262,5k | N/D | 1981 |
Dr. Reshma P. Shetty | Founder, President, COO & Director | 262,5k | N/D | 1981 |
Mr. Mark E. Dmytruk | Chief Financial Officer | 476,5k | N/D | 1972 |
Mr. Thomas Knight Jr. | Founder | N/D | N/D | N/D |
Mr. Austin Che Ph.D. | Founder, Head of Strategy & Treasurer | N/D | N/D | N/D |
Mr. Bartholomew Canton | Founder, CTO & Secretary | N/D | N/D | N/D |
Mr. Steven P. Coen CPA | Chief Accounting Officer | N/D | N/D | N/D |
Karen Tepichin | General Counsel & Secretary | N/D | N/D | N/D |
Ms. Anna Marie Wagner | Senior Vice President of Corporate Development | N/D | N/D | N/D |
Ms. Samantha Sutton | Head of People | N/D | N/D | N/D |
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
L'ISS Governance QualityScore di Ginkgo Bioworks Holdings, Inc. al 1 maggio 2024 è 10. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 6; diritti degli azionisti: 10; retribuzione: 9.